Camptothecin sensitizes human hepatoma Hep3B cells to TRAIL-mediated apoptosis via ROS-dependent death receptor 5 upregulation with the involvement of MAPKs

Environmental Toxicology and Pharmacology

Volumn 38, Issue 3, 2014, Pages 959-967

  Jayasooriya, Rajapaksha Gedara Prasad Tharanga ^a   Choi, Yung Hyun ^b   Hyun, Jin Won ^c   Kim, Gi Young ^a  

^a Jeju National University   (South Korea)

^b Dong Eui University   (South Korea)

^c Jeju National University School of Medicine   (South Korea)

Author keywords

Camptothecin; Death receptor 5; Mitogen activated protein kinases; Reactive oxygen species; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

ACETYLCYSTEINE; CAMPTOTHECIN; CASPASE; DEATH RECEPTOR 5; GLUTATHIONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; HEPATOMA CELL; HUMAN; HUMAN CELL; UPREGULATION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; CAMPTOTHECIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84909585862     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2014.10.012     Document Type: Article

References (28)

1. Azijli K., Weyhenmeyer B., Peters G.J., de Jong S., Kruyt F.A. Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ. 2013, 20:858-868.
2. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., Goodwin R.G. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997, 7:813-820.
3. Ganten T.M., Koschny R., Haas T.L., Sykora J., Li-Weber M., Herzer K., Walczak H. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 2005, 42:588-597.
4. Ganten T.M., Koschny R., Sykora J., Schulze-Bergkamen H., Büchler P., Hass T.L., Schader M.B., Untergasser A., Stremmel W., Walczak H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res. 2006, 12:2640-2646.
5. Guan B., Yue P., Clayman G.L., Sun S.Y. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. Journal of Cellular Physiology 2001, 188:98-105.
6. Higuchi H., Grambihler A., Canbay A., Bronk S.F., Gores G.J. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J. Biol. Chem. 2004, 279:51-60.
7. Huang Y., Sheikh M.S. TRAIL death receptors and cancer therapeutics. Toxicol. Appl. Pharmacol. 2007, 224:284-289.
8. Inoue S., MacFarlane M., Harper N., Wheat L.M., Dyer M.J., Cohen G.M. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 2004, 11:S193-S206.
9. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
10. Jung E.M., Park J.W., Choi K.S., Park J.W., Lee H.I., Lee K.S., Kwon T.K. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species mediated upregulation of death receptor 5 (DR5). Carcinogensis 2006, 27:2008-2017.
11. Kim Y.H., Jung E.M., Lee T.J., Kim S.H., Choi Y.H., Park J.W., Park J.W., Choi K.S., Kwon T.K. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Rad. Biol. Med. 2008, 44:1055-1068.
12. Kim M.O., Moon D.O., Kang C.H., Kwon T.K., Choi Y.H., Kim G.Y. β-Ionone enhances TRAIL-induced apoptosis in hepatocellular carcinoma cells through Sp1-dependent upregulation of DR5 and downregulation of NF-κB activity. Mol. Cancer Therp. 2010, 9:833-843.
13. Lemke J., von Karstedt S., Zinngrebe J., Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 2014, 1-15.
14. Liu X.P., Zhou S.T., Li X.Y., Chen X.C., Zhao X., Qian Z.Y., Zhou L.N., Li Z.Y., Wang Y.M., Zhong Q., Yi T., Li Z.Y., He X., Wei Y.Q. Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model. J. Exp. Clin. Cancer Res. 2010, 29:76.
15. Moon D.O., Kim M.O., Choi Y.H., Kim G.Y. Butein sensitizes human hepatoma cells to TRAIL-induced apoptosis via extracellular signal-regulated kinase/Sp1-dependent DR5 upregulation and NF-κB inactivation. Mol. Cancer Therap. 2010, 9:1583-1595.
16. Palacios C., Yerbes R., López-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res. 2006, 66:8858-8869.
17. Pan P., Li Y., Yu H., Sun H., Hou T. Molecular principle of topotecan resistance by topoisomerase I mutations through molecular modeling approaches. J. Chem. Inform. Model. 2013, 53:997-1006.
18. Ravi R., Bedi G.C., Engstrom L.W., Zeng Q., Mookerjee B., Gélinas C., Fuchs E.J., Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat. Cell Biol. 2001, 3:409-416.
19. Roberts N.J., Zhou S., Diaz L.A., Holdhoff M. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2011, 2:739-751.
20. Sheikh M.S., Burns T.F., Huang Y., Wu G.S., Amundson S., Brooks K.S., Formace A.J., el-Deiry W.S. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor. Cancer Res. 1998, 58:1593-1598.
21. Srivastava R.K. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001, 3:535-546.
22. Strumberq D., Pilon A.A., Smith M., Hickey R., Malkas L., Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. Mol. Cell. Biol. 2000, 20:3977-3987.
23. Sun M., Zhang J., Liu S., Liu Y., Zheng D. Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells. Oncol. Reports 2008, 19:177-185.
24. Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C., McLaughin M.M., Srinvasula S.M., Livi G.P., Marshall L.A., Alnemri E.S., Williams W.V., Doyle M.L. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 2000, 275:23319-23325.
25. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999, 5:157-163.
26. Wall M.E., Wani M.C., Natschke S.M., Nicholas A.W. Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminate Decne: total synthesis and biological activity. Med. Chem. 1986, 29:1553-1555.
27. Wang L.M., Li Q.Y., Zu Y.G., Fu Y.J., Chen L.Y., Lv H.Y., Yao L.P., Jiang S.G. Anti-proliferative and pro-apoptotic effect of CPT13, a novel camptothecin analog, on human colon cancer HCT8 cell line. Chemico-Biol. Interactions 2008, 176:165-172.
28. Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008, 27:6207-6215.